Avacta joint venture to collaborate with Chinese biological company
(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.
Read moreThu, 22nd Sep 2016 15:56
(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.
Read moreAvacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 million from GBP18.9 million in 2020. However, revenue rises to GBP2.9 million from GBP2.1 million. Like the year before, there will be no dividends.
Read more(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.
Read more(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.
Read more(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.
Read moreAvacta shares up 12% after chemotherapy drug advances to next stage
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.
Read moreAvacta selects potential tumour treatment for preclinical development
Read moreAIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers
Read moreLONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony
Read moreAbingdon Health plunges after Avacta stops selling Covid-19 test
Read moreAIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests
Read more(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.
Read moreAvacta shares drop as Covid tests show reduced sensitivity to Omicron
Read moreLONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures
Read more